Summary
Pyrazole (NSC-45410) is a low molecular weight, heterocyclic compound which has been considered for reevaluation in the clinic as a potential cytotoxic agent (Fig. 1). Discovered in 1893 [1], pyrazole is best known as an inhibitor of liver alcohol dehydrogenase (ki= 0.2 uM), and as a result, has been used extensively in studies of alcohol metabolism [2]. In 1960, pyrazole was identified as being active in preclinical antitumor models [3], which led to preliminary clinical testing [4,5]. The early Phase I studies were not followed by disease specific Phase II trials, and the clinical activity of the drug has never been evaluated. This omission was noted by the National Cancer Institute's Project for the Review of Old Drugs (PROD), at which time it was also noted that pyrazole is selectively toxic to thyroid tissue in an animal model [6]. Hence, interest in pyrazole was revived for two reasons: (a) failure to screen it for clinical activity in the 1960's, and (b) current interest in discovering drugs with selective toxicity to specific tissues for evaluation of their activity in malignancies arising in the target tissue. In this review, we summarize the evidence which has accumulated concerning pyrazole's potential role as an anticancer agent.
Similar content being viewed by others
References
Buchner E, Fritsch M: Darstellung and derivate des freien pyrazols. Liebigs Ann 273:256–266, 1893
Theorell H, Yonetani T: Liver alcohol dehydrogenase-DPN-pyrazole complex: a model of ternary intermediate in the enzyme reaction. Biochem Zeitschrift 338:537–553, 1963
Pyrazole report: The John L. Smith Memorial for Cancer Research/Chas. Pfizer & Co., Inc., Maywood, New Jersey, July 1960
Wilson WL and Bottiglieri NG: Phase I studies with pyrazole. Cancer Chemother Rep 21:137–141, 1962
Foley HT, Schnider BI, Gold GL and Uzer Y: Phase I studies of pyrazole (NSC 45410). Cancer Chemother Rep 44:45–48, 1965
Szabo S, Horvath E, Kovacs K and Larsen PR: Pyrazoleinduced thyroid necrosis: a distinct organ lesion. Science 199:1209–1210, 1978
Theorell H and Yonetani T: On the effects of some heterocyclic compounds on the enzymic activity of liver alcohol dehydrogenase. Acta Chem Scand 23:255–260, 1969
Dahlbom R, Tolf BR, Akeson A, Lundquist G and Theorell H: On the inhibitory power of some further pyrazole derivatives of horse liver alcohol dehydrogenase. Biochem Biophys Res Comm 57:549–553, 1974
Lieber CS, Rubin E, Decarli LM, Misra P and Gang H: Effects of pyrazole on hepatic function and structure. Lab Invest 22:615–622, 1970
Juvonen RO, Kaipainen PK and Lang MA: Selective induction of coumarin 7-hydroxylase by pyrazole in D2 mice. Eur J Biochem 152:3–8, 1985
Rouach H, Ribiere C, Nordmann J and Nordmann R: Effects of pyrazole of rat liver tryptophan oxygenase. Life Sci 19:505–514, 1976
Fiala ES and Stathopoulos C: Metabolism of methylazoxymethanol acetate in the F344 rat and strain-2 guinea pig and its inhibition by pyrazole and disulfiram. J Cancer Res Clin Oncol 108:129–134, 1984
Moriya M, Harada T and Shirasu Y: Inhibition of carcinogenicities of 1,2-dimethylhydrazine and azoxymethane by pyrazole. Cancer Lett 17:147–152, 1982
Moriya M, Ohta T, Watanabe K, Sugiyama F, Miyazawa T and Shirasu Y: Inhibitors for the mutagenicities of colon carcinogens, 1,2-dimethylhydrazine and azoxymethane, in the host-mediated assay. Cancer Lett 7:325–330, 1979
Evarts RP, Raab MM, Haliday E and Brown C: Pyrazole effects on mutagenicity and toxicity of dimethylnitrosamine in Wistar rats. Cancer Res 43:496–499, 1983
Craft JA: Effects of pyrazole on nitrosodimethylamine demethylase and other microsomal xenobiotic metabolizing activities. Biochem Pharm 34:1507–1513, 1985
Cederbaum AI and Rubin E: Effects of pyrazole, 4-bromopyrazole and 4-methylpyrazole on mitochondrial function. Biochem Pharm 23:203–213, 1974
Marselos M, Orronen RD, Alakuijala P and Macdonald E: Hepatic hydroxylation and glucuronidation in the rat after subacute pyrazole treatment. Toxicology 8:251–261, 1977
MacDonald E, Marselos M and Nousiainen U: Central and peripheral catecholamine levels after pyrazole treatment. Acta Pharm Tox 37:106–112, 1975
MacDonald E: Effects of pyrazole treatment on physical status and brain biogenic amines in rats. Med Biol 55:101–108, 1977
Eales JG and Omeljaniuk RJ: Effect of pyrazole on thyroid function in rainbow trout, Salmo gairdneri. Gen Comp Endocrin 45:279–282, 1981
Clay KL, Watkins WD and Murphy RC: Metabolism of pyrazole. Structure elucidation of urinary metabolites. Drug Metab Dispos 5:149–156, 1977
Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute. In vivo cancer models 1976–1982. U.S. Government Printing Office, NIH Publication No. 8-2635, February 1984
Shoemaker RH, Wolpert-Defilippes MK, Kern DH, Lieber MM, Makuch RW, Melnick NR, Miller WT, Salmon SE, Simon RM, Venditti JM and Von Hoff DD: Application of a human tumor colony-forming assay to new drug screening. Cancer Res 45:2145–2153, 1985
Hahn M-A and Adamson RH: Pharmacology of 3,5-diamino-1,2,4-triazole (guanazole). 1. Antitumor activity of guanazole. J Natl Cancer Inst 48:783–790, 1972
Magnusson G, Nyberg JA, Bodin NO and Hansson E: Toxicity of pyrazole and 4-methylpyrazole in mice and rats. Experientia 28:1198–1200, 1972
Rydberg U, Buijten T and Neri A: Kinetics of some pyrazole derivatives in the rat. J Pharm Pharmacy 24:651–652, 1972
Rydberg U and Buijten JC: Determination and identification of pyrazole derivatives by gas chromatography-mass spectrometry. J Chrom 64:170–173, 1972
Lester D and Benson GD: Alcohol oxidation in rats inhibited by pyrazole, oximes, and amides. Science 169:282–283, 1970
Al-Baldawi NFH and Brown EG: Metabolism of the amino acid B-pyrazol-1-ylalanine and its parent base pyrazole. Biochem Pharmacol 34:1273–1278, 1985
Author information
Authors and Affiliations
Additional information
Investigational Drug Branch, Cancer Therapy Evaluation Program
Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute
Address for offprints: P.J. O'Dwyer, Fox Chase Cancer Center, Central and Shelmire Avenues, Philadelphia, PA 19111 USA
Rights and permissions
About this article
Cite this article
O'Dwyer, P.J., King, S.A., Plowman, J. et al. Pyrazole: preclinical reassessment. Invest New Drugs 6, 305–310 (1988). https://doi.org/10.1007/BF00173649
Issue Date:
DOI: https://doi.org/10.1007/BF00173649